;PMID: 3305049
;source_file_2915.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..130] = [t:44..130]
;2)section:[e:134..176] = [t:134..176]
;3)sentence:[e:180..309] = [t:180..309]
;4)sentence:[e:310..443] = [t:310..443]
;5)sentence:[e:444..611] = [t:444..611]
;6)sentence:[e:612..674] = [t:612..674]
;7)sentence:[e:675..774] = [t:675..774]
;8)sentence:[e:775..857] = [t:775..857]
;9)sentence:[e:858..1008] = [t:858..1008]
;10)sentence:[e:1009..1087] = [t:1009..1087]
;11)sentence:[e:1088..1248] = [t:1088..1248]
;12)sentence:[e:1249..1419] = [t:1249..1419]
;13)section:[e:1423..1467] = [t:1423..1467]

;section 0 Span:0..38
;Exp Cell Res.  1987 Aug;171(2):367-75.
(SEC
  (FRAG (NNP:[0..3] Exp) (NNP:[4..8] Cell) (NNP:[9..12] Res) (.:[12..13] .)
        (CD:[15..19] 1987) (CC:[20..28] Aug;171-LRB-) (CD:[28..29] 2)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..34] 367)
        (HYPH:[34..35] -) (CD:[35..37] 75) (.:[37..38] .)))

;sentence 1 Span:44..130
;Heat shock gene expression and cytoskeletal alterations in mouse
;neuroblastoma  cells.
;[44..54]:gene-rna:"Heat shock"
;[109..122]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP
      (NML (NN:[44..48] Heat) (NN:[49..54] shock))
      (NN:[55..59] gene) (NN:[60..70] expression))
    (CC:[71..74] and)
    (NP (JJ:[75..87] cytoskeletal) (NNS:[88..99] alterations))
    (PP-LOC (IN:[100..102] in)
      (NP (NN:[103..108] mouse) (NN:[109..122] neuroblastoma)
          (NNS:[124..129] cells)))
    (.:[129..130] .)))

;section 2 Span:134..176
;van Bergen en Henegouwen PM, Linnemans AM.
(SEC
  (FRAG (NNP:[134..137] van) (NNP:[138..144] Bergen) (NNP:[145..147] en)
        (NNP:[148..158] Henegouwen) (NNP:[159..161] PM) (,:[161..162] ,)
        (NNP:[163..172] Linnemans) (VBP:[173..175] AM) (.:[175..176] .)))

;sentence 3 Span:180..309
;The cytoskeleton of neuroblastoma cells, clone Neuro 2A, is altered by two 
;stress conditions: heat shock and arsenite treatment.
;[200..213]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[180..183] The) (NN:[184..196] cytoskeleton))
      (PP (IN:[197..199] of)
        (NP
          (NP (NN:[200..213] neuroblastoma) (NNS:[214..219] cells))
          (,:[219..220] ,)
          (NP (NN:[221..226] clone) (NN:[227..232] Neuro) (NN:[233..235] 2A)))))
    (,:[235..236] ,)
    (VP (VBZ:[237..239] is)
      (VP (VBN:[240..247] altered)
        (NP-1 (-NONE-:[247..247] *))
        (PP (IN:[248..250] by)
          (NP-LGS
            (NP (CD:[251..254] two) (NN:[256..262] stress)
                (NNS:[263..273] conditions))
            (::[273..274] :)
            (NP
              (NP (NN:[275..279] heat) (NN:[280..285] shock))
              (CC:[286..289] and)
              (NP (NN:[290..298] arsenite) (NN:[299..308] treatment)))))))
    (.:[308..309] .)))

;sentence 4 Span:310..443
;Microtubules are  reorganized, intermediate filaments are aggregated around
;the nucleus, and the  number of stress fibers is reduced.
(SENT
  (S
    (S
      (NP-SBJ-1 (NNS:[310..322] Microtubules))
      (VP (VBP:[323..326] are)
        (VP (VBN:[328..339] reorganized)
          (NP-1 (-NONE-:[339..339] *)))))
    (,:[339..340] ,)
    (S
      (NP-SBJ-2 (JJ:[341..353] intermediate) (NNS:[354..363] filaments))
      (VP (VBP:[364..367] are)
        (VP (VBN:[368..378] aggregated)
          (NP-2 (-NONE-:[378..378] *))
          (PP-LOC (IN:[379..385] around)
            (NP (DT:[386..389] the) (NN:[390..397] nucleus))))))
    (,:[397..398] ,) (CC:[399..402] and)
    (S
      (NP-SBJ-3
        (NP (DT:[403..406] the) (NN:[408..414] number))
        (PP (IN:[415..417] of)
          (NP (NN:[418..424] stress) (NNS:[425..431] fibers))))
      (VP (VBZ:[432..434] is)
        (VP (VBN:[435..442] reduced)
          (NP-3 (-NONE-:[442..442] *)))))
    (.:[442..443] .)))

;sentence 5 Span:444..611
;Since both stress modalities induce similar  cytoskeletal alterations, no
;thermic denaturation of one or more cytoskeletal  components can be involved
;in this process.
(SENT
  (S
    (SBAR-ADV (IN:[444..449] Since)
      (S
        (NP-SBJ (DT:[450..454] both) (NN:[455..461] stress)
                (NNS:[462..472] modalities))
        (VP (VBP:[473..479] induce)
          (NP (JJ:[480..487] similar) (JJ:[489..501] cytoskeletal)
              (NNS:[502..513] alterations)))))
    (,:[513..514] ,)
    (NP-SBJ-1
      (NP (DT:[515..517] no) (JJ:[518..525] thermic)
          (NN:[526..538] denaturation))
      (PP (IN:[539..541] of)
        (NP
          (QP (CD:[542..545] one) (CC:[546..548] or) (JJR:[549..553] more))
          (JJ:[554..566] cytoskeletal) (NNS:[568..578] components))))
    (VP (MD:[579..582] can)
      (VP (VB:[583..585] be)
        (VP (VBN:[586..594] involved)
          (NP-1 (-NONE-:[594..594] *))
          (PP-CLR (IN:[595..597] in)
            (NP (DT:[598..602] this) (NN:[603..610] process))))))
    (.:[610..611] .)))

;sentence 6 Span:612..674
;Heat shock proteins are induced both  by heat and by arsenite.
;[612..622]:gene-protein:"Heat shock"
(SENT
  (S
    (NP-SBJ-1
       (NN:[612..616] Heat) (NN:[617..622] shock)
      (NNS:[623..631] proteins))
    (VP (VBP:[632..635] are)
      (VP (VBN:[636..643] induced)
        (NP-1 (-NONE-:[643..643] *))
        (PP (CC:[644..648] both)
          (PP (IN:[650..652] by)
            (NP-LGS (NN:[653..657] heat)))
          (CC:[658..661] and)
          (PP (IN:[662..664] by)
            (NP-LGS (NN:[665..673] arsenite))))))
    (.:[673..674] .)))

;sentence 7 Span:675..774
;However, cells treated with arsenite synthesize hsp28  which is not detected
;in heat-treated cells.
;[723..728]:gene-protein:"hsp28"
(SENT
  (S
    (ADVP (RB:[675..682] However))
    (,:[682..683] ,)
    (NP-SBJ
      (NP (NNS:[684..689] cells))
      (VP (VBN:[690..697] treated)
        (NP (-NONE-:[697..697] *))
        (PP-CLR (IN:[698..702] with)
          (NP (NN:[703..711] arsenite)))))
    (VP (VBP:[712..722] synthesize)
      (NP
        (NP (NN:[723..728] hsp28))
        (SBAR
          (WHNP-1 (WDT:[730..735] which))
          (S
            (NP-SBJ-1 (-NONE-:[735..735] *T*))
            (VP (VBZ:[736..738] is) (RB:[739..742] not)
              (VP (VBN:[743..751] detected)
                (NP-1 (-NONE-:[751..751] *))
                (PP-LOC (IN:[752..754] in)
                  (NP
                    (ADJP (NN:[755..759] heat) (HYPH:[759..760] -)
                          (VBN:[760..767] treated))
                    (NNS:[768..773] cells)))))))))
    (.:[773..774] .)))

;sentence 8 Span:775..857
;Synthesis of all hsps is prevented  by addition of actinomycin D or
;cycloheximide.
;[792..796]:gene-protein:"hsps"
;[826..839]:gene-protein:"actinomycin D"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[775..784] Synthesis))
      (PP (IN:[785..787] of)
        (NP (DT:[788..791] all) (NNS:[792..796] hsps))))
    (VP (VBZ:[797..799] is)
      (VP (VBN:[800..809] prevented)
        (NP-1 (-NONE-:[809..809] *))
        (PP (IN:[811..813] by)
          (NP-LGS
            (NP (NN:[814..822] addition))
            (PP (IN:[823..825] of)
              (NP
                (NP (NN:[826..837] actinomycin) (NN:[838..839] D))
                (CC:[840..842] or)
                (NP (NN:[843..856] cycloheximide))))))))
    (.:[856..857] .)))

;sentence 9 Span:858..1008
;Under these conditions no  alterations are observed in the organization of
;microtubules and intermediate  filaments during heat or arsenite treatment.
(SENT
  (S
    (PP (IN:[858..863] Under)
      (NP (DT:[864..869] these) (NNS:[870..880] conditions)))
    (NP-SBJ-1 (DT:[881..883] no) (NNS:[885..896] alterations))
    (VP (VBP:[897..900] are)
      (VP (VBN:[901..909] observed)
        (NP-1 (-NONE-:[909..909] *))
        (PP (IN:[910..912] in)
          (NP
            (NP (DT:[913..916] the) (NN:[917..929] organization))
            (PP (IN:[930..932] of)
              (NP
                (NP (NNS:[933..945] microtubules))
                (CC:[946..949] and)
                (NP (JJ:[950..962] intermediate) (NNS:[964..973] filaments))))
            (PP-TMP (IN:[974..980] during)
              (NP
                (NP (NN:[981..985] heat)
                  (NML-2 (-NONE-:[985..985] *P*)))
                (CC:[986..988] or)
                (NP (NN:[989..997] arsenite)
                  (NML-2 (NN:[998..1007] treatment)))))))))
    (.:[1007..1008] .)))

;sentence 10 Span:1009..1087
;However, these drugs are not able  to prevent the rapid loss of stress
;fibers.
(SENT
  (S
    (ADVP (RB:[1009..1016] However))
    (,:[1016..1017] ,)
    (NP-SBJ (DT:[1018..1023] these) (NNS:[1024..1029] drugs))
    (VP (VBP:[1030..1033] are) (RB:[1034..1037] not)
      (ADJP-PRD (JJ:[1038..1042] able)
        (S
          (NP-SBJ (-NONE-:[1042..1042] *))
          (VP (TO:[1044..1046] to)
            (VP (VB:[1047..1054] prevent)
              (NP
                (NP (DT:[1055..1058] the) (JJ:[1059..1064] rapid)
                    (NN:[1065..1069] loss))
                (PP (IN:[1070..1072] of)
                  (NP (NN:[1073..1079] stress) (NNS:[1080..1086] fibers)))))))))
    (.:[1086..1087] .)))

;sentence 11 Span:1088..1248
;A re-formation of the cytoskeleton  during the recovery period proceeds
;within 3 h and is also found to occur in the  presence of a protein synthesis
;inhibitor.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1088..1089] A) (AFX:[1090..1092] re) (HYPH:[1092..1093] -)
          (NN:[1093..1102] formation))
      (PP (IN:[1103..1105] of)
        (NP (DT:[1106..1109] the) (NN:[1110..1122] cytoskeleton)))
      (PP-TMP (IN:[1124..1130] during)
        (NP (DT:[1131..1134] the) (NN:[1135..1143] recovery)
            (NN:[1144..1150] period))))
    (VP
      (VP (VBZ:[1151..1159] proceeds)
        (PP-TMP (IN:[1160..1166] within)
          (NP (CD:[1167..1168] 3) (NN:[1169..1170] h))))
      (CC:[1171..1174] and)
      (VP (VBZ:[1175..1177] is)
        (ADVP (RB:[1178..1182] also))
        (VP (VBN:[1183..1188] found)
          (NP-1 (-NONE-:[1188..1188] *))
          (S-ADV
            (NP-SBJ (-NONE-:[1188..1188] *))
            (VP (TO:[1189..1191] to)
              (VP (VB:[1192..1197] occur)
                (PP (IN:[1198..1200] in)
                  (NP
                    (NP (DT:[1201..1204] the) (NN:[1206..1214] presence))
                    (PP (IN:[1215..1217] of)
                      (NP (DT:[1218..1219] a)
                        (NML (NN:[1220..1227] protein)
                             (NN:[1228..1237] synthesis))
                        (NN:[1238..1247] inhibitor)))))))))))
    (.:[1247..1248] .)))

;sentence 12 Span:1249..1419
;These data suggest that  reorganization of microtubules and intermediate
;filaments during a stress  treatment requires the synthesis of a new
;protein(s), probably hsp(s).
;[1412..1418]:gene-protein:"hsp(s)"
(SENT
  (S
    (NP-SBJ (DT:[1249..1254] These) (NNS:[1255..1259] data))
    (VP (VBP:[1260..1267] suggest)
      (SBAR (IN:[1268..1272] that)
        (S
          (NP-SBJ
            (NP (NN:[1274..1288] reorganization))
            (PP (IN:[1289..1291] of)
              (NP
                (NP (NNS:[1292..1304] microtubules))
                (CC:[1305..1308] and)
                (NP (JJ:[1309..1321] intermediate) (NNS:[1322..1331] filaments))))
            (PP-TMP (IN:[1332..1338] during)
              (NP (DT:[1339..1340] a) (NN:[1341..1347] stress)
                  (NN:[1349..1358] treatment))))
          (VP (VBZ:[1359..1367] requires)
            (NP
              (NP (DT:[1368..1371] the) (NN:[1372..1381] synthesis))
              (PP (IN:[1382..1384] of)
                (NP
                  (NP (DT:[1385..1386] a) (JJ:[1387..1390] new)
                      (NN:[1391..1401] protein-LRB-s-RRB-))
                  (,:[1401..1402] ,)
                  (NP
                    (ADVP (RB:[1403..1411] probably))
                    (NN:[1412..1418] hsp-LRB-s-RRB-)))))))))
    (.:[1418..1419] .)))

;section 13 Span:1423..1467
;PMID: 3305049 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1423..1427] PMID) (::[1427..1428] :) (CD:[1429..1436] 3305049)
        (NN:[1437..1438] -LSB-) (NNP:[1438..1444] PubMed) (::[1445..1446] -)
        (NN:[1447..1454] indexed) (IN:[1455..1458] for)
        (NNP:[1459..1467] MEDLINE-RSB-)))
